SNY logo

Sanofi (SNY)

$47.53

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on SNY

Market cap

$115.92B

EPS

3.76

P/E ratio

10.8

Price to sales

1.8

Dividend yield

5.089%

Beta

0.302286

Price on SNY

Previous close

$48.39

Today's open

$47.54

Day's range

$47.50 - $47.96

52 week range

$39.07 - $52.67

Profile about SNY

CEO

Belén Garijo

Employees

74846

Headquarters

Paris,

Exchange

Nasdaq Global Select

Shares outstanding

2.44B

Issue type

American Depository Receipt

SNY industries and sectors

Healthcare

Pharmaceuticals

News on SNY

Novavax Eyes New Partnerships as Sanofi Advances COVID-Flu Vaccine Trial

Novavax NASDAQ: NVAX is looking to expand partnerships around its vaccine technology while advancing a potential C. difficile vaccine and supporting partner Sanofi's development of a combination COVID-19 and flu shot, executives said at the Jefferies 2026 Global Healthcare Conference in London.

news source

MarketBeat • 20 hours ago

news preview

The world's most sophisticated drug companies are putting billions into vaccines — despite the political environment

Look at the promising data for Moderna and Merck's experimental cancer vaccine and the research suggesting the shingles vaccine can delay dementia.

news source

Market Watch • Nov 12, 2026

news preview

69 Dividend Champions Ranked By Quality Scores (November 2026)

I present 69 Dividend Champions with Dividend Safety scores of 8+ and rank them using my 9F Quality Scores system. Twenty-two featured Dividend Champions are undervalued, while 21 are overvalued. Forty-nine have quality scores ≥ 7.0, indicating high quality. Top candidates by style: BRO and BMI for growth; BRO, BMI, and RGLD (below $262) for total return; CTBI for income; CAT for past performance.

news source

Seeking Alpha • Nov 7, 2026

news preview

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (November 2026)

This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields 3.7%, we present two other groups of five DGI stocks, each with moderate to high yields of up to 8%.

news source

Seeking Alpha • Nov 7, 2026

news preview

Nurix, Sanofi Diverge — And One Breaks Out — On A Shocking Eczema Development

Shares of Nurix Therapeutics crashed Wednesday after Sanofi unexpectedly scrapped an experimental eczema drug that two were codeveloping.

news source

Investors Business Daily • Nov 4, 2026

news preview

Dupixent Is Still Booming. Sanofi's CEO Is Already Planning for Life Without It

Sanofi SA (NASDAQ:SNY) on Friday reported third-quarter sales of $16.623 billion (14.444 billion euros), beating the consensus of $15.23 billion. Sales increased 16.2% year over year, up 14.3% in constant currency.

news source

Benzinga • Oct 30, 2026

news preview

Sanofi Q3 Earnings Call Highlights

Sanofi NASDAQ: SNY reported third-quarter 2026 sales growth of 14.3% at constant exchange rates, supported by continued demand for Dupixent, recently launched medicines and growth in rare diseases. The company also raised its full-year sales and business EPS outlook while outlining a strategy focused on immunology, rare diseases and vaccines.

news source

MarketBeat • Oct 30, 2026

news preview

Sanofi CEO Sets Sights on Deals to Drive Turnaround

The French drugmaker is moving to fill its medicine pipeline to prepare for the looming patent expiration of its bestselling product, Dupixent.

news source

WSJ • Oct 30, 2026

news preview

Sanofi Q3 Earnings & Sales Beat, 2026 View Up, Shares Rise

SNY beats Q3 earnings and sales estimates as Dupixent drives growth and the company raises its 2026 outlook for sales and business EPS.

news source

Zacks Investment Research • Oct 30, 2026

news preview

Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up

A strong third quarter has made Regeneron Pharmaceuticals (NASDAQ:REGN | REGN Price Prediction) a standout healthcare gainer on a day when tech stocks are selling off. In morning trading, Regeneron stock has climbed to $919.58, up 12%.

news source

24/7 Wall Street • Oct 30, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Sanofi

Open an M1 investment account to buy and sell Sanofi commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in SNY on M1